Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.[ Read More ]
The intrinsic value of one MYNZ stock under the base case scenario is HIDDEN Compared to the current market price of 0.239 USD, Mainz Biomed B.V. is HIDDEN
Current Assets | 8.98 M |
Cash & Short-Term Investments | 7.07 M |
Receivables | 355 K |
Other Current Assets | 1.55 M |
Non-Current Assets | 6.43 M |
Long-Term Investments | 0 |
PP&E | 3.03 M |
Other Non-Current Assets | 3.39 M |
Current Liabilities | 9.24 M |
Accounts Payable | 2.33 M |
Short-Term Debt | 5.22 M |
Other Current Liabilities | 1.69 M |
Non-Current Liabilities | 2.92 M |
Long-Term Debt | 2.2 M |
Other Non-Current Liabilities | 727 K |
Revenue | 895 K |
Cost Of Revenue | 386 K |
Gross Profit | 510 K |
Operating Expenses | 27.2 M |
Operating Income | -26.6 M |
Other Expenses | -349 K |
Net Income | -26.3 M |
Net Income | -26.3 M |
Depreciation & Amortization | 866 K |
Capital Expenditures | -1.9 M |
Stock-Based Compensation | 4.01 M |
Change in Working Capital | -64.6 K |
Others | -751 K |
Free Cash Flow | -23.8 M |
Date | Value | Insider | Amount | Avg Price |
---|